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Objective: Despite the growing number of point-of-
care (POC) tests available, little research has assessed
primary care clinician need for such tests. We therefore
aimed to determine which POC tests they actually use or
would like to use (if not currently available in their
practice).
Design: Cross-sectional survey.
Setting: Primary care in Australia, Belgium (Flanders
region only), the Netherlands, the UK and the USA.
Participants: Primary care doctors (general
practitioners, family physicians).
Main measures: We asked respondents to (1) identify
conditions for which a POC test could help inform
diagnosis, (2) from a list of tests provided: evaluate
which POC tests they currently use (and how frequently)
and (3) determine which tests (from that same list) they
would like to use in the future (and how frequently).
Results: 2770 primary care clinicians across five
countries responded. Respondents in all countries
wanted POC tests to help them diagnose acute
conditions (infections, acute cardiac disease, pulmonary
embolism/deep vein thrombosis), and some chronic
conditions (diabetes, anaemia). Based on the list of POC
tests provided, the most common tests currently used
were: urine pregnancy, urine leucocytes or nitrite and
blood glucose. The most commonly reported tests
respondents expressed a wish to use in the future were:
D-dimer, troponin and chlamydia. The UK and the USA
reported a higher actual and desired use for POC tests
than Australia, Belgium and the Netherlands. Our limited
data suggest (but do not confirm) representativeness.
Conclusions: Primary care clinicians in all five
countries expressed a desire for POC tests to help them
diagnose a range of acute and chronic conditions. Rates
of current reported use and desired future use were
generally high for a small selection of POC tests, but
varied across countries. Future research is warranted to
explore how specific POC tests might improve primary
care.
BACKGROUND
Diagnostic testing forms the backbone of a
large proportion of primary healthcare,
informing decisions about treatment, spe-
cialty referral and hospital admission. Over
the past few decades, diagnostic technologies
have become cheaper, smaller, and in some
cases more accurate. A wide range and
growing1 2 number of point-of-care (POC,
‘near patient’) tests which provide rapid ‘on
site’ results are now available. These may
have potential to improve outcomes in
primary care by optimising prescribing deci-
sions, reducing referrals, improving effi-
ciency of care and decreasing costs.3 10
While growing in number, POC tests have
not generally been adopted in primary care
in many high-income settings. A recent sys-
tematic review of primary care clinicians’ atti-
tudes towards blood POC tests highlighted a
number of barriers, as well as potential
Strengths and limitations of this study
▪ This is the first survey assessing primary care
clinician (family doctor) use and desire for
point-of-care tests.
▪ In total, 2770 respondents across five countries
(Australia, Belgium, the Netherlands, the UK and
the USA) responded to the survey.
▪ The study identified a clinical need for a variety of
point-of-care tests that will inform policy deci-
sions about which tests might be used in primary
care, and industry strategy regarding which
point-of-care tests require further development.
▪ Response rates varied across countries, and rep-
resentativeness (although suggestive) could not
be confirmed.
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facilitators, to their wider adoption in primary care.11
Barriers included concerns about accuracy, over-reliance
on tests and limited usefulness. Facilitators included
improved diagnostic certainty, targeting of treatment,
communication and shared decisions. Concern about
the evidence base for the effectiveness of POC tests was
noted over 15 years ago12 and remains a problem, with
few high-quality studies focusing on patient outcomes
(rather than test accuracy).13
Understanding which POC tests primary care clini-
cians (general practitioners, family physicians) consider
priorities could bridge the gap between the number of
tests available and the number actually used in primary
care. Understanding clinician priorities has also been
shown as a key step in the successful development (by
industry) and implementation of new tests.14 Yet an obs-
tacle to assessing priorities is that clinicians may cur-
rently be unaware of some newly available technologies,
and are unlikely to know what could feasibly be devel-
oped in the (near) future. Likewise, industry may not be
familiar with the tests or research avenues that are likely
to benefit general practice. In spite of the many benefits
of understanding which POC tests clinicians find useful,
there has been little effort to assess primary care clin-
ician needs (or perceived needs) for POC tests.5
Our aim was therefore to conduct an international
survey of primary care clinicians in five countries with
well-developed yet different primary care health systems:
Australia, Belgium, the Netherlands, the UK and the
USA. Specifically, we aimed: (1) to identify the condi-
tions for which general practitioners would find POC
tests useful to help them make diagnostic decisions, (ii)
evaluate which POC tests primary care clinicians use in
their current practice and (iii) determine what POC
tests they would like to use but are not currently avail-
able in their practices. An advantage of our approach
was that the questions focused on the conditions for




We conducted an international cross-sectional survey of
primary care clinicians in Australia, Belgium (Flanders
region only), the Netherlands, the UK and the USA.
The survey
We first asked primary care clinicians to identify up to
five health conditions for which POC testing might help
them to in making diagnostic decisions. We specified
that they could list the condition whether or not a POC
test currently exists (in the UK version of the survey we
also asked similar questions about reducing referrals and
monitoring acute conditions. Because these questions
were not asked in other countries we do not report
them in this international report. These data will be
reported separately). Respondents also had the option
to state: “I do not believe POC Tests would help me
make a diagnosis.” Next, we presented a list of 50 tests
and asked respondents to identify which tests were avail-
able to them and they currently used as POC tests. All
50 tests were POC blood, urine or other specimen tests
(as opposed to POC devices such as blood pressure
monitors or electrocardiography). We did not require
respondents to specify the condition for which they
might use the test. Respondents were then presented
with the same list (minus the tests they previously stated
were already available to them) and asked them to indi-
cate which they would wish to have available as a POC
test in their practice. Hence, for each of the 50 tests
primary care clinicians could indicate 1 of 4 options:
1. (Current use) This test is available as a POC test in
my practice and I use it.
2. (Current use) This test is available as a POC test in
my practice, but I do not use it.
3. (Desired use) This test is not available as a POC test
in my practice, but I would use it if were available.
4. (Desired use) This test is not available as a POC test
in my practice, and I would not use it if it were
available.
For respondents who stated that they either currently
used or desired to use a test, we followed up with a ques-
tion about how frequently they used/desired to use the
test (at least once daily, weekly, monthly, once per year
or less).
Finally, respondents were asked to indicate the dis-
tance between their practice and the nearest emergency
department, how long it took them (on average) to get
results from a blood test, the type of location of their
practice (urban, rural), the number of registered
patients in their practice, how many hours per week
they worked (on average), their year of qualification,
age and sex. The complete version of the UK survey is
in online supplementary appendix VI.
Survey development and implementation
After development by five authors ( JH, CJ, MT, CH and
JWLC) the survey was checked for relevance and omis-
sions by authors in all countries, pilot tested by 30
primary care clinicians in the UK and adjusted accord-
ingly. The list of 50 tests used in the survey was based on
the most commonly ordered laboratory tests by primary
care in Oxfordshire, UK, and was modified based on
input from general practitioners in other countries. The
survey underwent additional changes to make it relevant
to each country. For example, the Australian version did
not ask about use or desire for protein/creatinine ratio
because protein/creatinine ratio is known in Australia as
albumin:creatinine ratio (ACR) or urinary microalbu-
min; leucocytes/nitrites testing was excluded from the
Australian survey due to survey length restrictions.
Neither Belgium nor the Netherlands asked about use/
desire for prothrombin time testing because of overlap
(and therefore confusion) with international normalised
ratio (INR). The survey was translated to Dutch for the
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Netherlands and Belgium (translation led by JWLC) so
respondents could complete the survey in their own lan-
guage. In Belgium, the Netherlands, the UK and the
USA, the surveys were conducted using online survey
tools. In Australia the survey was conducted both online
and via postal mailings (see table 1). Up to three remin-
ders were sent in each country.
Our target sample size ranged between 357 (for
Belgium with 5000 practising family care physicians) and
383 (for the USA with 208, 807 primary care physicians)
based on 95%±5% CI and an estimated proportion of
50%.15 16
Statistical analyses
Data were entered and analysed using Excel.
Respondent characteristics were compared with known
characteristics of primary care clinicians in each country,
based on publically available data on primary care clin-
ician characteristics.
We categorised responses to the open-ended question
(about conditions for which respondents would like POC
tests to help them make diagnoses) using the
International Classification of Primary Care (ICPC-2-R)17
system (see online supplementary appendix VII). We
then generated frequencies of responses using SPSS
(V.21) or (in Australia) Stata (V.13). Some modification
of the ICPC-2-R was required to account for the
responses. For example, many respondents listed cancer
as a condition for which they would like a POC test, yet
cancer is not currently a condition in the ICPC hand-
book. We also combined some conditions. For example,
many respondents listed pulmonary embolism (PE) and
deep vein thrombosis (DVT) as a single condition,
whereas others listed these separately, so we combined PE
and DVT into a single category. Four authors ( JH, MT,
JWLC and AVdB) were responsible for modifying the
coding frame. One person conducted the coding in each
country, and ambiguities were resolved by discussion with
additional authors. Descriptive statistics were used to
display frequencies for each (adapted) ICPC-2-R condi-
tion, and a list was compiled of all tests that were actually
used or desired by at least 25% of respondents in each
individual country. The individual country data for tests
that at least 25% of respondents either use or would use
are reported in the web appendix, tables I-V. These tables
also provide details about how frequently respondents
used (or would use) the test.
RESULTS
Sample characteristics
A total of 2770 primary care clinicians responded to the
survey (see table 1). Response rates varied from 10%
(Australia) to 68% (UK). Between 29% (USA) and 43%
(UK) of the respondents were women, and the average
distance between the practice and the nearest hospital
ranged from 7.1 (Belgium) to 11.2 km (UK). The propor-
tion of rural/semirural respondents ranged from 25%
(USA) to 55% (Belgium). The average year of qualifica-
tion ranged from 1988 (Australia) to 1993 (UK).
Representativeness
Australian respondents reported working fewer hours
per week than the national average (28 vs 33) and there
was an over-representation of rural respondents (44%
rural, whereas the national average is 30%).18 In
Belgium 40% of respondents were women and the
average year of qualification was 1990, whereas on
average 28% of primary care clinicians are women and
the average year of qualification is 1987 in the region.19
Respondents in the Netherlands were similar to national
averages in terms of age (average age 48.9 years and
national average 48.5 years), and average number of
hours worked per week (44 for respondents and
national average).20 Respondents in the UK were repre-
sentative of UK general practitioners in terms of per-
centage female (43% of respondents and 48% UK
general practitioners) and median year of qualification:
1996 for respondents and 1997 for national average
(national average data provided median but not mean,
whereas table 1 reports mean in order to retain consist-
ency with data reported in other countries).21 In the
USA the sample had fewer female respondents (29%)
than the national average (39%) and the proportion of
rural respondents was slightly higher among respon-
dents (25%) than the national average (19%).22 These
results suggest that our samples were broadly representa-
tive, yet the lack of comparative national average data
prevents us from drawing firm conclusions.
Conditions for which primary care clinicians would like to
use a POC test to help make a diagnosis
Table 2 displays the top 10 conditions which primary
care clinicians most commonly reported wanting POC
tests to help them diagnose. The most commonly listed
conditions by country were: urinary tract infection
(Australia, the UK and the USA) and PE/DVT (Belgium
and the Netherlands). Respondents in all five countries
included urinary tract infections, diabetes, acute cardiac
disease and anaemia among the top 10 conditions.
Respondents in at least four countries included heart
failure and PE/DVT among the top 10 conditions.
POC tests that primary care clinicians currently use
Table 3 shows current use of POC tests, ranked in des-
cending order according to the total percentage of
primary care clinicians who currently use each test.
Blood glucose, urine pregnancy test and urine leuco-
cytes or nitrite were the most frequently used POC tests
in the five countries, all being used by more than 80%
of respondents. Beyond the top three tests, frequency of
current use differed across countries. Overall, more
respondents in the UK and the USA reported using
POC tests than respondents in the other countries. At
least 10% of respondents reported using 47 of the tests
in the USA and 46 of the tests in the UK. The number
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Table 1 Characteristics of respondents in each country
Country Australia Belgium The Netherlands UK USA
Total number of
respondents
298 319 639 1109 405
Response rate 10% NA 30% 68% NA
Dates of data
collection
Sent out May 2013, one
reminder, closed in October
2013
Sent out February 2013, no










Female (%) NA 131 (40) 239 (37) 475 (43) 119 (29)
Kilometres to nearest
hospital (average)
NA 7.1 8.6 11.2 7.9
Location of practice
Rural or semirural 280 (44%) 176 (55%) 280 (44%) 377 (34%) 102 (25%)




NA 2800 4110 8275 NA
Sampling method 2933 GPs Australian Medical
Association membership list
with addition of data from other
sources (approximately 80%
GPs covered)
Existing mailing list of GPs and
GP groups in the region were
contacted. The survey was
only sent to GPs in Flanders
(the Flemish speaking part of
Belgium)











network and a randomly
sampled group of practitioners,
stratified according to age,





Academic networks and GP






Doctors.net Practice Based Research
Network and commercial polling
agency
Type of survey Electronic and paper Electronic Electronic Electronic Electronic
Year qualified as a
doctor: average
1988 1990 1991 1993 1990



















 on 15 October 2018 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2014-005611 on 8 August 2014. Downloaded from 
Table 2 Conditions for which respondents would like a point-of-care test to help them diagnose conditions: top 10 in each country












Diabetes 57 (170) PE/DVT 94 (300) PE/DVT 106.5 (651)* UTI 47 (521) UTI 56 (225)
Acute cardiac disease 42 (126) Acute cardiac disease 76 (241) Acute cardiac
disease
62.7 (383) PE/DVT 43 (478) Strep throat 54 (218)
UTI 32 (95) Heart failure 24 (75) Chest infection/
cough/LRTI
54.7 (334) Diabetes 35 (385) Diabetes 42 (169)
Pregnancy 26 (79) Chest infection/
cough/LRTI
24 (75) UTI 26.0 (159) Acute cardiac
disease
25 (282) Influenza 40 (162)
Anaemia 18 (53) Infections 23 (74) Heart failure 22.9 (140) INR/anticoagulation 18 (199) Pregnancy 25 (103)
Chronic and acute renal
conditions (excluding UTI)
15 (45) UTI 19 (61) Anaemia 20.0 (122) Pregnancy 16 (178) Infectious
mono
14 (56)
INR/anticoagulation 17 (51) Acute and chronic
renal impairment
12 (39) Diabetes 14.7 (90) Anaemia 15 (162) Anaemia 13 (52)
PE/DVT 13 (40) Diabetes 12 (37) Infections 13.1 (80) Heart failure 11 (124) STDs 7 (27)
Heart failure 12 (37) Anaemia 8 (24) Appendicitis 10.8 (66) COPD/asthma 10 (116) INR 7 (27)
COPD/asthma 12 (35) STDs 7 (21) STDs 9.0 (55) Chest infection/
cough/LRTI
9 (102) Acute cardiac
disease
6 (23)
*>100% Since we combined PE and DVT. This is because some respondents in the Netherlands listed both PE and PE/DVT. In other countries we faced similar problems. Since it was
impossible to split PE from DVT when respondents listed PE/DVT as a single condition, we lumped them together.
COPD, chronic obstructive pulmonary disease; DVT, deep vein thrombosis; INR, international normalised ratio; LRTI, lower respiratory tract infection; PE, pulmonary embolism; STD, sexually
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of tests reported as used by at least 10% of respondents
in the other countries was lower: five in Australia, seven
in Belgium and nine in the Netherlands. The number
of tests used could be a function of practice size (which
was much higher in the UK than other countries where
it was reported, see table 1).
A POC test for INR was used by nearly half of the
Australian, American and British primary care clinicians,
compared with only 1% (6/639, 95% CI 0% to 2%) of
the Dutch and 12% (37/319, 95% CI 9% to 16%) of
Belgian (Flemish) primary care clinicians. Haemoglobin
tests were used by more respondents in the Netherlands
(58%, 371/639, 95% CI 54% to 62%) and the USA
(50%, 202/405, 95% CI 45% to 55%) than in other
countries. Haemoglobin use was 16% (174/1109, 95%
CI 14% to 18%) in the UK, 3% (8/319, 95% CI 1% to
5%) in Belgium and 10% (29/298, 95% CI 7% to 12%)
in Australia. POC tests were used by a higher proportion
of respondents in the USA compared with other coun-
tries. For example, 60% used throat swabs for influenza
and 86% tested for group A streptococci, while these
tests were used by between 0% and 15% of primary care
clinicians in the other countries. Similarly, 83% of US
doctors used faecal occult blood tests, while only 2–18%
of primary care clinicians in the other countries used
this POC test. C reactive protein (CRP) was used by 48%
(305/639, 95% CI 44% to 52%) of the Dutch primary
care clinicians, in contrast with less than 15% in the
other countries (see table 3 for details).
Desired POC tests (that primary care clinicians do not
currently use but would use if available)
Desired use was higher than reported current use, sug-
gesting a demand for POC tests (see table 4). Overall 19
tests were desired by at least 50% of respondents in at
least one country, while only 8 tests were actually used by
at least 50% of respondents in at least one country. POC
tests for D-dimer, troponin, chlamydia, gonnorrhoea,
B-type natriuretic peptide, CRP, glycated haemoglobin,
white cell count and haemoglobin were desired by more
than half of respondents across all countries.
Desire for POC tests was highest in the UK, where at
least 50% of respondents expressed the desire to use 18
of the listed tests. The numbers of tests desired by at
least 50% of respondents in other countries were: 12
(Belgium), 11 (US A), 6 (the Netherlands) and 1
(Australia). Reported current use seemed to be inversely
correlated with higher desired use. For example, INR
actual use in the Netherlands (1%, 6/639, 95% CI 0%
to 2%) and Belgium (12%, 37/319, 95% CI 9% to 16%)
was low, yet desire for INR was higher in Belgium (77%,
244/319, 95% CI 72% to 81%) and the Netherlands
(54%, 347/639, 95% CI 50% to 58%) than in other
countries.
DISCUSSION
This international survey of primary care clinicians indi-
cates a desire for POC tests to help diagnose a range of
acute (infections and acute cardiopulmonary) condi-
tions and some chronic conditions (such as diabetes
and anaemia). The most frequently used POC tests used
currently (blood glucose, urine pregnancy and urine
leucocytes/nitrites) only partially correspond with the
conditions for which primary care clinicians would like
POC tests to help them make diagnoses (urinary tract
infection, PE/DVT and acute cardiac disease, diabetes
and anaemia). This suggests an unmet clinical need for
a more widely accessible range of POC tests to assist clin-
icians with immediate decisions (urgent referrals, or
immediate treatment decisions such as the decision to
treat with antibiotics).
Table 3 Point-of-care tests that at least 25% of respondents in at least one country reported currently using, ranked in













Urine pregnancy test 68% (203) 61% (193) 94% (603) 80% (887) 86% (350) 81% (2236)
Urine leucocytes or nitrite NA 87% (275) 96% (611) 90% (993) 88% (355) 81% (2234)
Blood glucose 74% (221) 87% (278) 96% (616) 69% (760) 82% (334) 80% (2209)
INR 48% (144) 12% (37) 1% (6) 43% (476) 47% (189) 31% (852)
Haemoglobin 10% (29) 3% (8) 58% (371) 16% (174) 50% (202) 28% (784)
Faecal occult blood 6% (19) 18% (56) 2% (14) 13% (143) 83% (335) 20% (567)
Throat swab for group A
streptococci
6% (19) 4% (12) 1% (4) 15% (164) 86% (348) 20% (547)
C reactive protein 3% (8) 3% (10) 48% (305) 15% (163) 10% (42) 19% (528)
Quantitative β-human
chorionic gonadotropin
6% (18) 19% (59) 22% (138) 17% (193) 28% (112) 19% (520)
HbA1c 6% (17) 2% (6) 6% (38) 17% (183) 40% (162) 15% (406)
Nose/throat swab for
influenza
7% (20) 1% (3) 0% (2) 6% (61) 60% (242) 12% (328)
Platelet count 4% (11) 0% (1) 1% (3) 15% (163) 28% (112) 10% (290)
HbA1c; glycated haemoglobin; INR, international normalised ratio; NA, not applicable.
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While there were similarities between countries in
terms of the tests used and the conditions for which
respondents expressed a desire for POC tests, there were
also important differences. Both actual use and reported
desired use was higher in the UK and the USA (see web
appendices I–V). Different reimbursement methods
across countries are likely to influence actual use, as well
as attitudes towards future use. For instance, the low
uptake of INR POC testing in Belgium could be due to
the fact that INR POC tests are not reimbursed, whereas
the regular laboratory INR test would be. The
Netherlands also reported lower INR usage, which could
be because there are separate thrombosis clinics moni-
toring anticoagulation therapy in the Netherlands. In
Australia, although INR is not reimbursed (whereas a
centralised laboratory test would be), primary care clini-
cians still use it because it improves patient flow and
management. Another source of intercountry variability
could be differences between practice set-ups. Rural
primary care clinicians in Australia or the USA are often
far more isolated than rural clinicians in Europe, and
ruling out a serious condition that requires immediate
transfer to the nearest hospital has important logistical
consequences. The differences in reimbursement and
care models across countries for POC tests need to be
explored further to discover whether and how specific
POC tests might improve patient outcomes in specified
settings. Other factors that could affect intercountry
variability include: type of reimbursement (fixed price
vs test cost), space and the need to accommodate a
range of technologies, staff time and the need to train
staff on a range of technologies, the need to change
clinic organisation expertise, expertise, regulatory
requirements and uncertainty about test accuracy.
Strengths and limitations
This is the first international survey of primary care clini-
cians on this topic. Our responses were internally vali-
dated by asking about both desire for POC tests (from a
specified list) as well as conditions for which respon-
dents would like a POC test to help them make a diag-
nosis. The results of the survey suggest that there is good
agreement between the conditions for which POC tests
are considered useful, and POC tests primary care clini-
cians would like to use in the future.
Response numbers exceeded target numbers in three
countries, and we were able to estimate representative-
ness by comparing characteristics of respondents with
the characteristics of primary care clinicians in each
country for many important variables. However, repre-
sentativeness could not be confirmed with certainty due
to limited data about national primary care clinician
characteristics. Specifically, over-representation of
primary care clinicians interested in POC testing could
have occurred despite high response rates in some coun-
tries. We also cannot assume, based on this survey, that
Table 4 Point-of-care tests that at least 50% of respondents in at least one country would use, ranked in descending order













D-dimer 41% (121) 83% (265) 70% (448) 73% (811) 62% (251) 68% (1896)
Troponin 43% (129) 85% (271) 65% (418) 69% (765) 59% (238) 66% (1821)
Chlamydia 49% (145) 67% (212) 60% (382) 65% (721) 66% (267) 62% (1727)
B-type natriuretic peptide 28% (82) 51% (164) 62% (398) 66% (734) 60% (244) 59% (1622)
C reactive protein 38% (114) 75% (238) 47% (302) 61% (682) 45% (181) 55% (1517)
Gonorrhoea 34% (100) 56% (180) 51% (326) 58% (645) 65% (262) 55% (1513)
HbA1c 52% (156) 61% (195) 37% (239) 61% (679) 50% (202) 53% (1471)
White cell count 43% (127) 67% (212) 40% (256) 60% (661) 52% (212) 53% (1468)
Haemoglobin 47% (139) 47% (150) 26% (168) 72% (793) 39% (159) 51% (1409)
Potassium 33% (97) 47% (150) 33% (210) 61% (679) 57% (232) 49% (1368)
International normalised
ratio
21% (63) 77% (244) 54% (347) 47% (517) 43% (176) 49% (1347)
Nose/throat swab for
influenza
43% (128) 59% (187) 36% (231) 55% (609) 33% (134) 47% (1289)
Erythrocyte sedimentation
rate
29% (86) 40% (128) 29% (183) 58% (645) 48% (194) 45% (1236)
Quantitative β-human
chorionic gonadotropin
40% (120) 56% (177) 23% (149) 53% (586) 46% (187) 44% (1219)
Creatinine 34% (102) 41% (130) 28% (177) 53% (593) 53% (214) 44% (1216)
Thyroid stimulating hormone 32% (95) 33% (105) 27% (171) 53% (586) 62% (253) 44% (1210)
Throat swab for group A
streptococci
35% (103) 60% (190) 33% (208) 53% (588) 11% (45) 41% (1134)
Uric acid 28% (82) 30% (94) 26% (167) 50% (549) 51% (205) 40% (1097)
Sodium 30% (88) 21% (66) 19% (122) 51% (571) 42% (172) 37% (1019)
HbA1c; glycated haemoglobin.
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the results can be generalised to other countries, espe-
cially low-income or middle-income countries.
It was somewhat surprising that some respondents
reported a desire to use some tests that should (in prin-
ciple) already be widely available. For example, potas-
sium tests have been available in the USA for over two
decades and take less than 3 min to conduct. Yet 57%
(232/405, 95% CI 52% to 62%) of US respondents
expressed a desire to use potassium POC tests in the
future. This suggests the possibility that respondents mis-
understood the question, provided invalid responses or
that the test was not available in their practice. Some of
the tests, for example, tests for acute cardiac disease,
may not be suitable or relevant in all countries.
However, this represents a mismatch between tests that
may be available commercially, yet not available to a par-
ticular respondent in their particular clinic. Further
research is warranted to investigate this issue.
Implications for clinicians, policymakers and industry
Conditions that primary care clinicians claim POC tests
would help them diagnose, as well as POC tests that are
widely desired, deserve further research and industry
development to assess their roles within evidence-based
diagnostic pathways. Studies of POC test clinical effect-
iveness will depend on adherence to quality control pro-
tocols, while cost-effectiveness studies will have to
address known barriers to cost-effectiveness of diagnostic
studies in general, and POC testing in particular,23 as
well as the barriers to implementation such as concerns
about the over-reliance on tests. Existing data about cost-
effectiveness of POC testing to date are mixed. The
potential for POC tests to reduce costs, for example, by
reducing the number of clinic visits24 is not always borne
out in practice.25 Cost-effectiveness will also be test and
setting specific: an Australian trial indicated that POC
testing resulted in a reduction in costs for some tests
(ACR) but greater for others (INR).26 Future research is
warranted to determine the clinical utility and cost-
effectiveness of individual tests (or clusters of tests).24
More research is also warranted to investigate the bar-
riers to implementation, some of which we have studied
previously.11 27 Once this research is done, tests which
are likely to improve patient care in a cost-effective way
require targeting by industry for development and opti-
misation. Tests used in low-prevalence settings have par-
ticular problems that may require independent
investigations.28
CONCLUSION
Primary care practitioners are eager to use a variety of
POC tests. Some conditions for which POC tests are
deemed most useful are similar across five countries
despite important differences in healthcare organisa-
tion. Future research is now warranted to investigate
how and whether these POC tests can improve patient
outcomes in a cost-effective way.
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